NOXXON Announces Appointment of Oscar Izeboud to the Supervisory Board & Provides Results of the Annual General Shareholders ...
02 Juillet 2020 - 8:00AM
Business Wire
Regulatory News:
NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth
Paris: ALNOX), a biotechnology company focused on improving
cancer treatments by targeting the tumor microenvironment (TME),
announced today that the annual general shareholders meeting (AGM)
held on Tuesday, June 30, 2020 appointed Dr. C. A. (Oscar) Izeboud
to the supervisory board and approved all voting items.
Shareholders representing a total of 18.55% of the total issued and
outstanding share capital on June 2, 2020 were represented by
proxy.
“We are very pleased to welcome Oscar to the NOXXON supervisory
board. He brings both a deep understanding of medicine and
extensive experience in the financing and business side of
biotechnology. While leading life science & healthcare banking
at Kempen and NIBC, Oscar successfully closed more than 100
transactions, including 17 IPOs and 15 mergers or acquisitions.
This experience combined with his operational biotech background
will be incredibly valuable to refine and implement NOXXON’s
strategy,” said Maurizio PetitBon, Chairman of NOXXON Pharma. Dr.
Izeboud’s term on the supervisory board is effective June 30, 2020
and will run for two years until the annual general meeting of
shareholders to be held in 2022.
Dr. Izeboud is CEO of Scenic Biotech, a drug discovery and
development company focused on genetic modifiers, based in the
Netherlands. Before joining Scenic Biotech, Dr. Izeboud was
Managing Director at NIBC Bank N.V. in Amsterdam, where he headed a
life sciences and healthcare team and led corporate finance and
capital markets activities with a focus on innovative companies.
Prior to that, as Managing Director at Kempen & Co., a Dutch
investment bank, he built the Life Sciences and Healthcare
franchise and played a pivotal role in numerous international
transactions in biotech, medtech, and the healthcare industry.
Before his transition to the banking sector, Dr. Izeboud’s initial
interest was in the biotech industry where he spent a number of
years working for Crucell NV, Specs BV, and TNO Pharma.
Dr. Izeboud has been a nonexecutive member of the board of
directors of Luciole Medical AG since 2019. He holds a Ph.D. in
immunopharmacology from the University of Utrecht in the
Netherlands.
The presentation outlining the agenda items and voting results
of the AGM is available online. The minutes of the AGM will soon be
made available on the NOXXON website (www.noxxon.com).
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking
the tumor protection barrier and blocking tumor repair. By
neutralizing chemokines in the tumor microenvironment, NOXXON’s
approach works in combination with other forms of treatment to
weaken tumor defenses against the immune system and enable greater
therapeutic impact. Building on extensive clinical experience and
safety data, the lead program NOX-A12 has delivered top-line data
from a Keytruda® combination trial in metastatic colorectal and
pancreatic cancer patients and further studies are being planned in
these indications. In September 2019 the company initiated an
additional trial with NOX-A12 in brain cancer in combination with
radiotherapy. The combination of NOX-A12 and radiotherapy has been
granted orphan drug status in the US and EU for the treatment of
certain brain cancers. The company’s second clinical-stage asset
NOX-E36 is a Phase 2 TME asset targeting the innate immune system.
NOXXON plans to test NOX‑E36 in patients with solid tumors both as
a monotherapy and in combination. Further information can be found
at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme
Corp
https://www.linkedin.com/company/noxxon-pharma-ag
https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future
results of business segments, financial indicators, developments of
the financial situation or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking
statements as certain prognoses of actual future events and
developments. The company is neither responsible nor liable for
updating such information, which only represents the state of
affairs on the day of publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200701005785/en/
NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief
Executive Officer Tel. +49 (0) 30 726247 0
amangasarian@noxxon.com
Trophic Communications Gretchen Schweitzer or Joanne
Tudorica Tel. +49 (0) 89 2388 7730 or +49 (0) 176 2103 7191
schweitzer@trophic.eu
NewCap Arthur Rouillé Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr